Life Sciences Reverse Mergers Gain Momentum & Attention

For life sciences companies, reverse merger transactions have become increasingly popular. However, merging into a public life sciences company that has experienced a failed clinical program often raises heightened SEC scrutiny and raises legal considerations. During this session, we will discuss:

Structuring alternatives;
Recent transactions structured as reverse mergers into public companies;
SEC comments in connection with recent reverse mergers;
Documentation, process and timeline;
New SEC Rule 145a and considerations to avoid shell company status;
Accounting for reverse acquisitions under US GAAP;
Accompanying PIPE and other financing transactions; and
Addressing board and employee matters, anticipating litigation and mitigating liability for the board of the new company.

For additional information, please contact Caitlin Kaplan at ckaplan@mayerbrown.com or +1 212 506 2103.